This document is a patent application (US20260086081A1) filed with the USPTO on April 10, 2025. It discloses novel spinal cord models utilizing a cell scaffold made from methacrylated hyaluronic acid (HAMA) and dopamine-modified hyaluronic acid (HA-Cat). These models are designed to regulate organoid patterning and vascularization, and can be co-cultured with blood vessel organoids to create blood-spinal cord barrier models.

This patent application does not impose immediate regulatory obligations. However, it signals potential future developments in regenerative medicine and tissue engineering. Companies involved in biotechnology, drug development, or medical device manufacturing, particularly those focused on neural tissue engineering or organoid technology, should monitor this patent's progress and consider its implications for their research and development strategies.